We are live on ! Find out more
ATXI

Avenue Therapeutics, Inc. Common Stock
ATXI

Delisted

ATXI was delisted on the 18th of March, 2025.

Back to rankings

10 hedge funds and large institutions have $766K invested in Avenue Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

323% more capital invested

Capital invested by funds: $181K → $766K (+$585K)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

33% less funds holding

Funds holding: 15 → 10 (-5)

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

Holders
10
Holders Change
-5
Holders Change %
-33.33%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
2
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$153K
2
Two Sigma Investments
Two Sigma Investments
New York
+$61.2K
3
TSS
Two Sigma Securities
New York
+$53.2K
4
Morgan Stanley
Morgan Stanley
New York
+$6.4K
5
TRCT
Tower Research Capital (TRC)
New York
+$5.12K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$36K
2
Renaissance Technologies
Renaissance Technologies
New York
-$34K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$22K
4
BRWA
B. Riley Wealth Advisors
Florida
-$16K
5
HF
HRT Financial
New York
-$10K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$362K +$153K +478 New
Two Sigma Investments
2
Two Sigma Investments
New York
$145K +$61.2K +191 New
TSS
3
Two Sigma Securities
New York
$143K +$53.2K +166 +722%
Wells Fargo
4
Wells Fargo
California
$46K – – –
BlackRock
5
BlackRock
New York
$20K – – –
Morgan Stanley
6
Morgan Stanley
New York
$15K +$6.4K +20 New
TRCT
7
Tower Research Capital (TRC)
New York
$14K +$5.12K +16 +533%
UBS Group
8
UBS Group
Switzerland
$11K -$4.16K -13 -46%
EL
9
EMFO LLC
Florida
$5K -$2.24K -7 -50%
Citigroup
10
Citigroup
New York
$5K +$2.24K +7 New
Vanguard Group
11
Vanguard Group
Pennsylvania
– -$36K -117 Closed
Renaissance Technologies
12
Renaissance Technologies
New York
– -$34K -111 Closed
Geode Capital Management
13
Geode Capital Management
Massachusetts
– -$22K -75 Closed
BRWA
14
B. Riley Wealth Advisors
Florida
– -$16K -52 Closed
HF
15
HRT Financial
New York
– -$10K -35 Closed
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
– -$7K -23 Closed
Northern Trust
17
Northern Trust
Illinois
– -$4K -12 Closed
CAN
18
Cetera Advisor Networks
California
– -$3K -10 Closed
Millennium Management
19
Millennium Management
New York
– -$3K -10 Closed
BNP Paribas Financial Markets
20
BNP Paribas Financial Markets
France
– -$2 – –

ATXI Hedge Fund Activity: Q3 2022 in Review

10 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q3 2022, worth a combined $766K — up 323% from $181K a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of ATXI and 4 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 2 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $153K. The largest seller was Vanguard Group, exiting entirely with an estimated $36K sold.

  • 10 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q3 2022, down from 15 in Q2 2022.
  • Funds reported $766K of Avenue Therapeutics, Inc. Common Stock stock for Q3 2022, up 323% quarter-over-quarter.
  • 4 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q3 2022 and 9 closed out, a net change of -5 holders.
  • The largest Avenue Therapeutics, Inc. Common Stock buyer in Q3 2022 was Citadel Advisors, an estimated $153K added.
  • The largest Avenue Therapeutics, Inc. Common Stock seller in Q3 2022 was Vanguard Group, an estimated $36K sold.

Based on aggregated 13F filings for Q3 2022.